Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAV680 in moderate persistent asthma
NCT01103037Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Sep 2010
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing QAV680 Arm with Placebo Arm (2 arms). Primary endpoint: Forced Expiratory Volume in one second at 28 days. Started Mar 2010; status: terminated.
02
Drugs
QAV680
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01103037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103037.